PRA Health Sciences Late Phase Services is participating in a global real world safety study program, mandated by various regulatory bodies, to confirm risk/benefit profile for a novel oral anticoagulant to assess the drug’s bleeding risk. Our ability to provide global operational oversight and efficiencies, ensure consistent communication with sites, and keep our patients engaged resulted in PRA becoming the client’s CRO of choice.
PRA in China
The expertise of a global CRO + local know-how to deliver the highest caliber of clinical development services around the world.
THE INSIGHT SERIES: Introduction to Myths and Misconceptions of Late Phase – Part 1
Late phase research has changed substantially over the past decade. During this period of innovation and development, many myths and misconceptions…